Investor insight: Mesa Laboratories’ SVP buys 8,893 shares and sells RSUs—mixed signals of confidence and liquidity that may stabilize the stock amid recent dips.
Insightful 13‑D analysis of Mesa Laboratories’ recent insider trade reveals routine portfolio rebalancing, not a red flag, amid promising clinical trial data and FDA milestones.